CD22 and cancer: The use of IMTXs in cancer therapy is an emergent field of study nowadays [1,2,3], with three approved constructions for the treatment of cancer: Denileukin difititox, targeting IL2R and the Diphteria toxin (DT) as the toxic domain; Tagraxofusp, also with DT as the toxic domain but targeting IL3R instead; and Moxetumomab pasudotox, targeting CD22 and with Pseudomonas exotoxin A as a toxic moiety [4,5].